Ascendis Pharma A/S (ASND)
After hours:
Chart Events
Performance Outlook
| Previous Close | 92.96 |
| Open | 92.56 |
| Bid | 92.50 x 800 |
| Ask | 92.63 x 1000 |
| Day's Range | 91.83 - 93.89 |
| 52 Week Range | 61.58 - 178.71 |
| Volume | |
| Avg. Volume | 518,157 |
| Market Cap | 5.167B |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ASND
Related Research
- Ascendis Pharma A/SDaily – Vickers Top Buyers & Sellers for 06/29/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat6 days agoArgus Research
- GlobeNewswire
Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for TransCon™ PTH to be a Replacement Therapy for Adult Hypoparathyroidism at ENDO 2022
– Late-breaker oral presentation of TransCon PTH Phase 3 PaTHway Trial data in adult hypoparathyroidism on Tuesday, June 14 – Oral presentation of TransCon PTH Phase 2 PaTH Forward Trial Open-Label Extension Data in adult hypoparathyroidism on Monday, June 13 – PaTHway Trial results represent the second consecutive successful pivotal Phase 3 trial of a TransCon product candidate COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its pre
- GlobeNewswire
Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial
- VISEN’s Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated with TransCon™ hGH demonstrated greater annualized height velocity at 52-weeks (p=0.0010) compared to patients treated with daily growth hormone - These results demonstrate the ability of TransCon technology to deliver consistent and reproducible results for patients across a broad range of geographies and populations COPENHAGEN, Denmark, May 23, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma
- GlobeNewswire
Ascendis Pharma A/S Announces New Commercial Endocrinology Leadership Appointments
- Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology - Scott A. Holmes has been appointed to the newly created role of Head of Global Commercial Strategy, Endocrinology - Jesper Høiland, Global Chief Commercial Officer, will retire and become a senior advisor to Ascendis Pharma - Endocrinology commercial team will continue to focus on building U.S. market leadership for SKYTROFA® (lonapegsomatropin-tcgd) and preparing for other anticipated TransCon™
